Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Natarajan MV et al. - Recurrent giant cell tumour was the most common tumour. The prosthesis used was a bipolar hinge custom mega prosthesis manufactured locally. Average follow-up was 78 months. The average Musculoskeletal Tumor Society functional score achieved was 75%. The ten-year prosthesis survival was rate 87.5%. Infection was the most common complication.


Today in Bone/Cartilage...keeping you current

Endoprosthetic proximal femur replacement: Metastatic versus primary tumors
Surgical Oncology, 11/05/09

Toxicity of Bisphosphonates
Journal of Palliative Medicine, 11/23/09

Survival in high-grade osteosarcoma: improvement over 21 years at a single institution
Annals of Oncology, 11/16/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address